OncoMatch/Clinical Trials/NCT07044635
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
Official title: Radiation Therapy in Reduced Dose and Hypofractionated Schedule After Trans-Oral Robotic Surgery in Intermediate Risk HPV-Mediated Oropharyngeal Squamous Cell Carcinoma
Is NCT07044635 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies non-drug interventions for oropharyngeal squamous cell carcinoma.
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A expression (positive)
p16 positivity or HPV positivity by in situ hybridization on pathological sampling of lymph node or primary oropharyngeal tumor
Required: HPV positive by in situ hybridization (positive)
p16 positivity or HPV positivity by in situ hybridization on pathological sampling of lymph node or primary oropharyngeal tumor
Required: HPV ttmv-hpv dna score ≤ 50 (≤ 50)
Pre-operative TTMV-HPV DNA score of ≤ 50
Excluded: HPV ttmv-hpv dna score > 50
Pre-operative TTMV-HPV DNA score of > 50
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy for mucosal head and neck cancer
History of prior mucosal head and neck cancer treated with radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute/University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07044635 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy for mucosal head and neck cancer disqualifies patients from enrollment.
Does this trial require CDKN2A?
Yes, CDKN2A expression is a required biomarker for enrollment.
Does this trial require HPV?
Yes, HPV positive by in situ hybridization is a required biomarker for enrollment.
Does this trial require HPV?
Yes, HPV ttmv-hpv dna score ≤ 50 is a required biomarker for enrollment.
Are patients with HPV alterations eligible?
No. HPV ttmv-hpv dna score > 50 is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages